Octagon Capital Advisors’s Tandem Diabetes Care TNDM Stock Holding History

Octagon Capital Advisors’s Portfolio TNDM Stock Details TNDM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-474,929	Closed	-$11.7M	–	45
2023 Q2	$11.7M	Hold	474,929	–	–	1.62%	14
2023 Q1	$19.3M	Hold	474,929	–	–	2.78%	11
2022 Q4	$21.3M	Hold	474,929	–	–	3.32%	9
2022 Q3	$22.7M	Buy	+474,929	New	+$26M	3.92%	6

Other funds holding TNDM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Eminence Capital New York $4.36B AUM 3.1% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Octagon Capital Advisors's TNDM Position: Q3 2023 in Review

Octagon Capital Advisors sold out of Tandem Diabetes Care (TNDM) in Q3 2023, closing a stake of 474,929 shares — an estimated $11.7M sold.

Octagon Capital Advisors first reported a position in TNDM in Q3 2022 and held it in 4 quarters. The position peaked at $22.7M in Q3 2022. 226 funds tracked by Wall St. Rank hold TNDM as of Q3 2023.

Octagon Capital Advisors reported no remaining Tandem Diabetes Care position as of Q3 2023 after selling out during the quarter.
Octagon Capital Advisors sold 474,929 Tandem Diabetes Care shares in Q3 2023, an estimated $11.7M.
Octagon Capital Advisors first reported a position in Tandem Diabetes Care in Q3 2022 and held it in 4 quarters.
Octagon Capital Advisors's Tandem Diabetes Care position peaked at $22.7M in Q3 2022.
226 funds tracked by Wall St. Rank held Tandem Diabetes Care as of Q3 2023.

Based on Octagon Capital Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.